Clinical efficacy of short-course chemotherapy combined with topical injection therapy in treatment of superficial lymph node tuberculosis
Metrics: PDF 671 views | HTML 1098 views | ?
Huiru An1, Zhongyuan Wang1, Hongbing Chen1, Tao Wang1, Xinjing Wang1, Lin Liu1, Xiao Liu1, Jing Xu1, Luxing He1, Kai Zhang1, Hongyan Zhang1 and Xinying Liu1
1Military Institute of Tuberculosis, Beijing, 100091, China
Zhongyuan Wang, email: firstname.lastname@example.org
Keywords: tuberculosis; lymph node; short-course chemotherapy; regional injection
Abbreviations: 6-month chemotherapy with isoniazid (H), rifampin (R) and ethambutol (E) (6HRE); the British Thoracic Society (BTS)
Received: July 04, 2017 Accepted: October 28, 2017 Published: November 18, 2017
To evaluate the clinical efficacy and safety of short-course chemotherapy combined with regional injection therapy in the treatment of superficial lymph node tuberculosis. 201 patients diagnosed with superficial lymph node tuberculosis were retrospectively analyzed. All patients were randomly divided into the study (n = 100) and control groups (n = 101). In the study group, the patients received 6-month chemotherapy with isoniazid (H), rifampin (R) and ethambutol (E) (6HRE) in combination with regional injection of streptomycin, and their counterparts in the control group underwent systemic regime of 3HRZE/6HRE. In the study group, the overall cure rate was calculated as 98% and the recurrence rate was 2%. Twenty-four of 25 nodular type patients and 36 among 37 inflammatory type patients were recovered and discharged. One patient with huge nodular type mass was treated for 4 months and the mass size was slightly reduced. In the control group, the overall cure rate was 48.5% and the recurrence rate was 7.9%. The recurrent patients were further administered with regional injection of streptomycin based upon the chemotherapy regime until they were recovered. Combined therapy of systemic chemotherapy and regional injection of streptomycin is probably an efficacious and safe approach in the treatment of superficial lymph node tuberculosis, which remains to be validated by more investigations.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.